Adrenergic alpha-Antagonists - Research News and Information

Wednesday, January 07, 2009

Association between 5-alpha reductase inhibition and risk of hip fracture.

6 Oct 2008 CONTEXT: For more than 15 years, 5-alpha reductase inhibitors, which block the conversion of testosterone to dihydrotestosterone, have been used in the treatment of benign prostatic hyperplasia (BPH). Short-term studies show no effects of these ... Read more...

[Conservative treatment of benign prostatic hyperplasia]

3 Oct 2008 Medical treatment of benign prostatic hyperplasia is reviewed by the author. Experiences with herbal extracts have been known for more than 2 decades. Treating benign prostatic hyperplasia with these extracts is recommended in initial phase. ... Read more...

Molecular engineering of conotoxins: the importance of loop size to alpha-conotoxin structure and function.

23 Sep 2008 Alpha-conotoxins are competitive antagonists of nicotinic acetylcholine receptors (nAChRs). The majority of currently characterized alpha-conotoxins have a 4/7 loop size, and the major features of neuronal alpha-conotoxins include a globular ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Adrenergic alpha-Antagonists'

These are the very latest articles for this heading:

• Association between 5-alpha reductase inhibition and risk of hip fracture. 6 Oct 2008
• [Conservative treatment of benign prostatic hyperplasia] 3 Oct 2008
• Molecular engineering of conotoxins: the importance of loop size to alpha-conotoxin structure and function. 23 Sep 2008
• Nuclear alpha1-adrenergic receptors signal activated ERK localization to caveolae in adult cardiac myocytes. 16 Sep 2008
• Letter by De Backer et al regarding article, "Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study". 31 Aug 2008
• Adenine nucleotide changes in the remnant liver: An early signal for regeneration after partial hepatectomy. 30 Aug 2008
• Emerging drugs for treatment of overactive bladder and detrusor overactivity. 30 Aug 2008
• Role of the multidomain protein spinophilin in blood pressure and cardiac function regulation. 16 Aug 2008
• Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus. 12 Aug 2008
• Dissociation between sympathetic nerve traffic and sympathetically mediated vascular tone in normotensive human obesity. 9 Aug 2008
• Immobilising free-ranging Alpine chamois with xylazine, reversed with atipamezole. 7 Aug 2008
• Alpha-1 adrenergic receptor transactivates signal transducer and activator of transcription-3 (Stat3) through activation of Src and epidermal growth factor receptor (EGFR) in hepatocytes. 30 Jul 2008
• Mirtazapine-induced akathisia. 30 Jul 2008
• Intrathecal clonidine suppresses phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit in spinal dorsal horn neurons of rats with neuropathic pain. 30 Jul 2008
• Possible mechanism of intraoperative floppy iris syndrome: a clinicopathological study. 30 Jul 2008
• Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs. 30 Jul 2008
• Benign prostatic hyperplasia and lower urinary tract symptoms in African Americans and Latinos: treatment in the context of common comorbidities. 30 Jul 2008
• Improving therapeutic outcomes in BPH through diagnosis, treatment and patient compliance. 30 Jul 2008
• Reversal of soft-tissue local anesthesia with phentolamine mesylate in adolescents and adults. 30 Jul 2008
• Reversal of soft-tissue local anesthesia with phentolamine mesylate in pediatric patients. 30 Jul 2008

See a longer list of these articles.

Technical information about 'Adrenergic alpha-Antagonists'

Definition: Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.

Registry Number: 0

Descriptor UI: D000317

Alternative terms: Adrenergic alpha-Antagonists; Adrenergic alpha Antagonists; alpha-Antagonists, Adrenergic; Adrenergic alpha-Receptor Blockaders; Adrenergic alpha Receptor Blockaders; Blockaders, Adrenergic alpha-Receptor; alpha-Receptor Blockaders, Adrenergic; alpha-Adrenergic Blocking Agents; Agents, alpha-Adrenergic Blocking; Blocking Agents, alpha-Adrenergic; alpha Adrenergic Blocking Agents; alpha-Adrenergic Blockers; Blockers, alpha-Adrenergic; alpha Adrenergic Blockers; alpha-Blockers, Adrenergic; alpha Blockers, Adrenergic; alpha-Adrenergic Receptor Blockaders; Blockaders, alpha-Adrenergic Receptor; Receptor Blockaders, alpha-Adrenergic; alpha Adrenergic Receptor Blockaders; Adrenergic alpha-Blockers; Adrenergic alpha Blockers;

Allowable Qualifiers: radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning;

Tree Number: D27.505.519.625.050.200.100; D27.505.696.577.050.200.100;

Online Note: use ADRENERGIC ALPHA-ANTAGONISTS to search ADRENERGIC ALPHA RECEPTOR BLOCKADERS 1969-94 (as Prov 1969-72)

History Note: 95; was ADRENERGIC ALPHA RECEPTOR BLOCKADERS 1969-94 (Prov 1969-72)

Technical Notes: GEN or unspecified; prefer specifics; do not confuse with ADRENERGIC ALPHA-AGONISTS; DF: ADREN ALPHA ANTAG